Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | ACP1 | P24666 | 1/20 | 0.49 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.49 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.49 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.48 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957559 | 0.85 | MRGPRX4 (0.54) | NPC1RAB9ASMN1; SMN2PDK2MRGPRX4 | |
| SCHEMBL682767 | 0.85 | MAPT (0.49) | NPC1RAB9ASMN1; SMN2MRGPRX4GLRA1 | |
| SCHEMBL26581179 | 0.85 | PDK2 (0.58) | NPC1RAB9ASMN1; SMN2PDK2MRGPRX4 | |
| SCHEMBL19736777 | 0.85 | PDK2 (0.49) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL13900992 | 0.84 | EGFR (0.53) | MRGPRX4 | |
| SCHEMBL38659146 | 0.84 | ACP1 (0.53) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL27299216 | 0.83 | SLC6A4 (0.47) | SMN1; SMN2PDK2 | |
| SCHEMBL12868786 | 0.83 | FFAR4 (0.54) | RAB9ASMN1; SMN2MRGPRX4GLRA1MAPT | |
| SCHEMBL12889910 | 0.83 | GLRA1 (0.50) | RAB9ASMN1; SMN2MRGPRX4GLRA1MAPT | |
| SCHEMBL24313779 | 0.81 | FFAR1 (0.52) | RAB9AMRGPRX4GLRA1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| US-8895583-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | NPC1 1195/4885RAB9A 963/4885SMN1; SMN2 3803/4885 |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A1, GUCY1A2 | NPC1 2280/4885RAB9A 989/4885SMN1; SMN2 1437/4885 |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | CYP19A1, CYP21A2, CBR1 | NPC1 4197/4885RAB9A 2155/4885SMN1; SMN2 4723/4885 |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | NPC1 1195/4885RAB9A 963/4885SMN1; SMN2 3803/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | NPC1 3132/4885RAB9A 821/4885SMN1; SMN2 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.